Erik Manting - 14 Jun 2024 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Reporting relationship: Director
Issuer ticker: RNAZ
Reported as of: 14 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2024, 16:16:30 UTC
Prior SEC filing: 19 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact

Key filing fact

Erik Manting filed Form 4 for Transcode Therapeutics, Inc. (RNAZ) on 18 Jun 2024.

Key facts

This page summarizes Erik Manting's Form 4 filing for Transcode Therapeutics, Inc. (RNAZ).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2024, 16:16.

Change

Previous filing in this sequence was filed on 19 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNAZ transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +70,000
Change %
Price: $0.000000
Shares after: 70,000
Date: 14 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,000
Exercise price: $1.20
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.